You know, Juozai, Lithuania is not interested in a quantum computer, even if it can be used free of charge through the cloud. What will you do with it? Cabbage leaven, instead of stone? Important for Lithuania are medications for Alzheimer's. Even Šimonytė is sick with Alzheimer's. She promises not to raise taxes during elections, and promises are forgotten after elections. And those Alzheimer’s drugs removing the amyloid that causes the disease from the brain, are already paying off.
"The study enrolled more than 250 patients in the U.S. and Canada with early symptoms of Alzheimer's who had evidence from imaging scans of amyloid and another substance called tau in their brains. About half received donanemab and the others received a placebo once a month for up to 72 weeks.
Researchers gave patients various tests at the start of the study to assess their cognitive and functional abilities, and then again 76 weeks after the start of treatment to detect changes. At baseline, the average score from these tests was 106 in both groups.
At 76 weeks, the scores of the patients in the placebo group dropped by an average of 10.06, while falling by 6.86 for those who took donanemab, for a 32% slowing of the decline.
Researchers said in the New England Journal of Medicine that the improvement was statistically significant but that it fell short of their goal of showing that donanemab would slow patients' decline by 50%.
The Lilly drug appeared to slow patients' declines using other measures in secondary analyses in the study. But the benefits in several of these secondary analyses at 76 weeks weren't statistically significant, meaning no firm conclusions could be drawn. This included a disease-staging scale known as CDR-SB, which has been a more common measure of effectiveness in Alzheimer's drug studies than the main measure that Lilly used in its study.
Lilly Chief Scientific Officer Dan Skovronsky said the results appeared to show that patients who received the drug had about the same level of cognitive skills after 18 months of treatment as the placebo recipients had after 12 months." [1]
1. Business News: Lilly Drug Shows Promise on Alzheimer's --- IV treatment modestly slows mental decline in patients, study finds
Loftus, Peter. Wall Street Journal, Eastern edition; New York, N.Y. [New York, N.Y]15 Mar 2021: B.3
Komentarų nėra:
Rašyti komentarą